Corvus Pharmaceuticals, Inc. (CRVS) Misses Q1 EPS by 1c
Tweet
Share
E-mail
Get Alerts CRVS Hot Sheet
Join SI Premium – FREE
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q1 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12).
For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blue Owl leads $2.4 billion debt deal for Iren data center
- IP Strategy Holdings receives Nasdaq noncompliance notice over late 10-Q
- Trilogy Metals signs $35.6M investment deal with U.S. Dept. of War
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
